Co-culture of placental stem cells and stem cells from a second source

• US 8,455,250 B2
• Filed: 12/28/2006
• Issued: 06/04/2013
• Est. Priority Date: 12/29/2005
• Status: Active Grant

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Heidaran, Mohammad, Wang, Jia-Lun, Ye, Qian, Zeitlin, Andrew, Delaney, Colleen Suzanne
• Primary Examiner(s): Weber, Jon P
• Assistant Examiner(s): SINGH, SATYENDRA K
• Application Number:
  US11/648,824
• Publication Number:
  US 20070292910A1
• Time in Patent Office: 2,350 Days
• Field of Search: None
• US Class Current: 435/373
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 2502/02 embryonic cells
• CPC Class Codes: C12N 2502/025 extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: G01N 33/56966 Animal cells

Abstract

The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.

Claims

1. A method of identifying a ratio of placental stem cells to stem cells from a second source, comprising combining and culturing a number of placental stem cells and a number of stem cells from a second source in a plurality of ratios for a time and under conditions sufficient to allow colony-forming units to form, and identifying the ratio in said plurality of ratios that produces a greater number of colony-forming units than a number of placental stem cells or stem cells from the second source, equivalent to the total number of placental stem cells and stem cells from the second source, alone, and produces the highest number of colony-forming units in said plurality of ratios.

2. The method of claim 1, wherein said placental stem cells are derived from a single placenta.

3. The method of claim 1, wherein said placental stem cells are derived from a plurality of placentas.

4. The method of claim 1, wherein said placental stem cells are stem cells from placental perfusate.

5. The method of claim 1, wherein said stem cells from the second source are cord blood-derived stem cells.

6. The method of claim 5, wherein said cord blood-derived stem cells are hematopoietic stem cells.

7. The method of claim 1, wherein said placental stem cells and the stem cells from the second source are combined in a suspension.

8. The method of claim 7 additionally comprising adding to said suspension a bioactive molecule.

9. The method of claim 8, wherein said bioactive molecule is a cytokine or a growth factor.

10. The method of claim 1, wherein said placental stem cells are obtained from a single individual.

11. The method of claim 1, wherein said placental stem cells are obtained from a plurality of individuals.

12. The method of claim 1, wherein said placental stem cells are CD34⁻

and not trophoblasts.

13. The method of claim 12, wherein said placental stem cells are CD34⁻

, CD10⁺, CD105⁺ (SH2⁺) and CD200⁺.

14. The method of claim 13, wherein said placental stem cells are additionally CD45⁻

and CD90⁺.

15. The method of claim 1, wherein said stem cells from the second source are hematopoietic stem cells.

16. The method of claim 15, wherein said hematopoietic stem cells from the second source are CD34⁺.

17. The method of claim 16, wherein said CD34⁺ cells are isolated from umbilical cord blood (UCB).

18. The method of claim 16, wherein said CD34⁺ cells are contained within UCB.